{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:18:37Z","timestamp":1790605117443,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.semarthrit.2022.152088","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T03:24:16Z","timestamp":1661916256000},"page":"152088","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["The Role of Myositis-Specific Autoantibodies and the Management of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: A Systematic Review"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6957-1632","authenticated-orcid":false,"given":"Aaron","family":"Teel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jielin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namisha","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pari","family":"Basharat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.semarthrit.2022.152088_bib0001","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10794","article-title":"Interstitial lung disease in polymyositis and dermatomyositis","volume":"47","author":"Marie","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.152088_bib0002","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1177\/0961203316651748","article-title":"Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease","volume":"25","author":"Nakashima","year":"2016","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152088_bib0003","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.autrev.2018.07.013","article-title":"Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta-analysis","volume":"18","author":"Barba","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152088_bib0004","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/14397595.2018.1553488","article-title":"KL-6 is a long-term disease-activity biomarker for interstitial lung disease associated with polymyositis\/dermatomyositis, but is not a short-term disease-activity biomarker","volume":"29","author":"Hanaoka","year":"2019","journal-title":"Mod Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152088_bib0005","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s10067-018-4353-2","article-title":"Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease","volume":"38","author":"Cobo-Ib\u00e1\u00f1ez","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.152088_bib0006","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/1346-8138.15049","article-title":"Clinical manifestations of skin, lung and muscle diseases in dermatomyositis positive for anti-aminoacyl tRNA synthetase antibodies","volume":"46","author":"Fukamatsu","year":"2019","journal-title":"J Dermatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152088_bib0007","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/art.21883","article-title":"Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis\/dermatomyositis","volume":"54","author":"Yamasaki","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152088_bib0008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154285","article-title":"Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated Gene 5 autoantibodies","volume":"11","author":"Sato","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.semarthrit.2022.152088_bib0009","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.rmed.2016.10.019","article-title":"Comprehensive assessment of myositis-specific autoantibodies in polymyositis\/dermatomyositis-associated interstitial lung disease","volume":"121","author":"Hozumi","year":"2016","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152088_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120313","article-title":"Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis\/dermatomyositis-associated interstitial lung disease: a retrospective case control study","volume":"10","author":"Hozumi","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152088_bib0011","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3899\/jrheum.161480","article-title":"Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies","volume":"44","author":"Shi","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152088_bib0012","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jocn.2020.01.060","article-title":"Serological risk factors for concomitant interstitial lung disease in patients with idiopathic inflammatory myopathy","volume":"74","author":"Huang","year":"2020","journal-title":"J Clin Neurosci"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152088_bib0013","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","article-title":"A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies","volume":"56","author":"Pinal-Fernandez","year":"2017","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152088_bib0014","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.resinv.2016.09.006","article-title":"Predictive factors for long-term outcome in polymyositis\/dermatomyositis-associated interstitial lung diseases","volume":"55","author":"Fujisawa","year":"2017","journal-title":"Respir Investig"},{"key":"10.1016\/j.semarthrit.2022.152088_bib0015","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jns.2018.12.040","article-title":"Myositis-specific autoantibodies in dermatomyositis\/polymyositis with interstitial lung disease","volume":"397","author":"Li","year":"2019","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.semarthrit.2022.152088_bib0016","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/1471-2474-11-223","article-title":"Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis","volume":"11","author":"Kang","year":"2010","journal-title":"BMC Musculoskelet Disord"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.152088_bib0017","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1007\/s10067-019-04503-7","article-title":"The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies","volume":"38","author":"Li","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152088_bib0018","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.resinv.2016.08.007","article-title":"Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis\/dermatomyositis-associated interstitial lung disease","volume":"55","author":"Yoshida","year":"2017","journal-title":"Respir Investig"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152088_bib0019","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s10067-019-04457-w","article-title":"Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody","volume":"38","author":"Jiang","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152088_bib0020","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/art.24621","article-title":"RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease","volume":"60","author":"Sato","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152088_bib0021","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152088_bib0022","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.resinv.2018.07.007","article-title":"Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis","volume":"56","author":"Sakamoto","year":"2018","journal-title":"Respir Investig"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.152088_bib0023","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/rheumatology\/keq153","article-title":"Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis","volume":"49","author":"Hoshino","year":"2010","journal-title":"Rheumatology"},{"issue":"19","key":"10.1016\/j.semarthrit.2022.152088_bib0024","doi-asserted-by":"crossref","first-page":"e1768","DOI":"10.1212\/WNL.0000000000008443","article-title":"More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.152088_bib0025","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.rmed.2014.09.003","article-title":"Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type","volume":"108","author":"Johnson","year":"2014","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152088_bib0026","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/acr.21895","article-title":"Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome","volume":"65","author":"Marie","year":"2013","journal-title":"Arthritis Care Res"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.152088_bib0027","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1002\/art.30513","article-title":"Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients","volume":"63","author":"Marie","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152088_bib0028","first-page":"58","article-title":"Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis","volume":"32","author":"Fujisawa","year":"2005","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152088_bib0029","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10067-017-3854-8","article-title":"Risk factors for the recurrence of interstitial lung disease in patients with polymyositis and dermatomyositis: a retrospective cohort study","volume":"37","author":"Nakazawa","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152088_bib0030","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13075-017-1506-7","article-title":"The predictive prognostic factors for polymyositis\/dermatomyositis-associated interstitial lung disease","volume":"20","author":"Sugiyama","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152088_bib0031","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/s10165-007-0553-3","article-title":"Step-up versus primary intensive approach to the treatment of interstitial pneumonia associated with dermatomyositis\/polymyositis: a retrospective study","volume":"17","author":"Takada","year":"2007","journal-title":"Mod Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152088_bib0032","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/RHU.0000000000000487","article-title":"Effective use of calcineurin inhibitor in combination therapy for interstitial lung disease in patients with dermatomyositis and polymyositis","volume":"23","author":"Shimojima","year":"2017","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152088_bib0033","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00296-015-3328-8","article-title":"Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease","volume":"36","author":"Go","year":"2016","journal-title":"Rheumatol Int"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152088_bib0034","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.rmed.2013.02.015","article-title":"A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis\/dermatomyositis","volume":"107","author":"IC","year":"2013","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152088_bib0035","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.chest.2019.05.023","article-title":"Long-term treatment with azathioprine and mycophenolate mofetil for myositis-related interstitial lung disease","volume":"156","author":"Huapaya","year":"2019","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152088_bib0036","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3760\/cma.j.issn.0366-6999.2010.05.002","article-title":"Predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis or dermatomyositis: a retrospective study","volume":"123","author":"SY","year":"2010","journal-title":"Chin Med J"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152088_bib0037","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3899\/jrheum.180778","article-title":"Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody-positive Polymyositis\/dermatomyositis-associated Interstitial Lung Disease: A Propensity Score-matched Analysis","volume":"46","author":"Hozumi","year":"2019","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152088_bib0038","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/archdermatol.2011.52","article-title":"Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study","volume":"147","author":"Hamaguchi","year":"2011","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152088_bib0039","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3109\/s10165-003-0205-1","article-title":"Efficacy of combination treatment with cyclosporin A and corticosteroids for acute interstitial pneumonitis associated with dermatomyositis","volume":"13","author":"Nagasaka","year":"2003","journal-title":"Mod Rheumatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.152088_bib0040","first-page":"1719","article-title":"Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute\/subacute interstitial pneumonia in patients with dermatomyositis","volume":"32","author":"Kameda","year":"2005","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152088_bib0041","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/rheumatology\/keu166","article-title":"The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis","volume":"54","author":"Kurita","year":"2015","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152088_bib0042","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/rheumatology\/kez394","article-title":"Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis\/dermatomyositis: a single-arm clinical trial","volume":"59","author":"Takada","year":"2020","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152088_bib0043","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1053\/sarh.2002.50012","article-title":"Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment","volume":"32","author":"Schnabel","year":"2003","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152088_bib0044","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3899\/jrheum.170541","article-title":"Rituximab in the treatment of interstitial lung disease associated with antisynthetase syndrome: a multicenter retrospective case review","volume":"45","author":"Doyle","year":"2018","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.152088_bib0045","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","article-title":"Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease","volume":"54","author":"Andersson","year":"2015","journal-title":"Rheumatology"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.152088_bib0046","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3899\/jrheum.150844","article-title":"Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: Anti-Ro52 positivity as a marker for severity and treatment response","volume":"43","author":"Bauhammer","year":"2016","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152088_bib0047","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152088_bib0048","doi-asserted-by":"crossref","first-page":"e89610","DOI":"10.1371\/journal.pone.0089610","volume":"9","author":"Isoda","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152088_bib0049","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1038\/s41598-017-01685-5","article-title":"Chemokine profiles of interstitial pneumonia in patients with dermatomyositis: a case control study","volume":"7","author":"Oda","year":"2017","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152088_bib0050","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/rheumatology\/kez357","article-title":"Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy","volume":"59","author":"Abe","year":"2020","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152088_bib0051","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/BOR.0000000000000663","article-title":"Pulmonary involvement in antisynthetase syndrome","volume":"31","author":"Gasparotto","year":"2019","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152088_bib0052","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1590\/S1806-37132011000100015","article-title":"Myositis-related interstitial lung disease and antisynthetase syndrome","volume":"37","author":"Solomon","year":"2011","journal-title":"J Bras Pneumol"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.152088_bib0053","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/acr.21985","article-title":"Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis","volume":"65","author":"Chen","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2022.152088_bib0054","doi-asserted-by":"crossref","unstructured":"Sabbagh, S., Pinal-Fernandez, I., Kishi, T., et\u00a0al. Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis, 78(7), 988\u2013995. https:\/\/doiorg.proxy1.lib.uwo.ca\/10.1136\/annrheumdis-2018-215004.","DOI":"10.1136\/annrheumdis-2018-215004"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152088_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2018.1521185","article-title":"Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists","volume":"29","author":"Kohsaka","year":"2019","journal-title":"Mod Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152088_bib0056","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrrheum.2018.42","article-title":"Treatment in myositis","volume":"14","author":"Oddis","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152088_bib0057","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11926-018-0731-7","article-title":"Management of interstitial lung disease in patients with myositis specific autoantibodies","volume":"20","author":"Mecoli","year":"2018","journal-title":"Curr Rheumatol Rep"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152088_bib0058","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/art.23571","article-title":"Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology","volume":"59","author":"Fathi","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.152088_bib0059","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s10067-015-3065-0","article-title":"The efficacy of tacrolimus in patients with refractory dermatomyositis\/polymyositis: a systematic review","volume":"34","author":"Ge","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152088_bib0060","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10067-014-2803-z","article-title":"Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review","volume":"34","author":"Ge","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"2-3","key":"10.1016\/j.semarthrit.2022.152088_bib0061","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s12026-013-8408-9","article-title":"Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature","volume":"56","author":"Nalotto","year":"2013","journal-title":"Immunol Res"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152088_bib0062","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00408-009-9146-6","article-title":"Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis\/dermatomyositis","volume":"187","author":"Suzuki","year":"2009","journal-title":"Lung"},{"issue":"21","key":"10.1016\/j.semarthrit.2022.152088_bib0063","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1056\/NEJM199205213262102","article-title":"Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis","volume":"326","author":"Miller","year":"1992","journal-title":"N Engl J Med"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222001391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222001391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:08:31Z","timestamp":1758733711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017222001391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":63,"alternative-id":["S0049017222001391"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152088","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Myositis-Specific Autoantibodies and the Management of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152088","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152088"}}